Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Renal Injury, Oncology, and Inflammation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NGAL/LCN2 drug discovery and diagnostic assay development. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LCN2/NGAL Recombinant Protein (Monomer & Heterodimer options) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View LCN2 Products |
| Gene Delivery | LCN2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View LCN2 Products |
| Benchmark Ab | Anti-LCN2 Recombinant Antibody Recombinant positive control for assay validation. |
View LCN2 Products |
| Validator | LCN2 siRNA Set For knockdown verification in target validation assays. |
View LCN2 Products |
| Related Target A | MMP9 (Matrix Metallopeptidase 9) Forms a physiological heterodimer complex with NGAL, protecting MMP9 from degradation. |
View MMP9 Products |
| Related Target B | SLC22A17 (LCN2R / 24p3R) High-affinity cell-surface receptor mediating NGAL-internalization and iron trafficking. |
View SLC22A17 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Monomer vs. Heterodimer Differentiation | Both monomeric LCN2 and pre-formed LCN2/MMP9 heterodimer proteins available, verified by SDS-PAGE and SEC-HPLC. |
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity for cross-reactivity screening. |
| Lack of Controls | Clinical-grade Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Sequence-verified siRNA pool included for target knockdown and specificity validation. |
Live NGAL/LCN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic and diagnostic exploitation of NGAL (Neutrophil Gelatinase-Associated Lipocalin, encoded by the LCN2 gene) is expanding rapidly. Long recognized as the gold-standard biomarker for Acute Kidney Injury (AKI), NGAL is now heavily investigated as a therapeutic target in oncology, chronic inflammatory diseases, and metabolic disorders. The next wave of R&D focuses on disrupting the NGAL/MMP9 interaction in solid tumors to inhibit metastasis, and blocking the NGAL/SLC22A17 pathway to modulate intracellular iron concentration in cancer stem cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic ELISA / IVD | Abbott Diagnostics, Roche, BioPorto | Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD) | High-affinity, glycosylated recombinant proteins (HEK293) to minimize batch-to-batch variation. |
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biopharma | Solid Tumors (Colorectal, Pancreatic), Renal Fibrosis | Epitope mapping against monomeric vs. dimeric NGAL (Need pure recombinant oligomers). |
| Small Molecules / Inhibitors | Preclinical Discovery | Iron-overload diseases, Inflammatory Bowel Disease (IBD) | Recombinant SLC22A17 (LCN2R) expressing stable cell lines for ligand-binding assays. |